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MaBACKGROUND Stemcell–based therapyhasemergedas apotential therapy in acutemyocardial infarction (AMI).Although
various approaches have been studied, intracoronary injection of bone marrow autologous mononuclear cells (BMMC) and
the ability of granulocyte colony-stimulating factor (G-CSF) tomobilize endogenous cells have attracted themost attention.
OBJECTIVES This study compares, for the ﬁrst time, the efﬁcacy of BMMC injection, G-CSF mobilization, and the
combination of both with standard treatment.
METHODS On Day 1 after primary percutaneous coronary intervention, 120 patients were randomized to a 1) intra-
coronary BMMC injection; 2) mobilization with G-CSF; 3) both (BMMC injection plus G-CSF); or 4) conventional treatment
(control group). G-CSF, 10 mg/kg/day subcutaneously, was started Day 1 and maintained for 5 days. BMMC injection was
performed on Days 3 to 5. Our primary endpoint was absolute change in 12-month left ventricular ejection fraction (LVEF)
and left ventricular end-systolic volume (LVESV) relative to baseline measured by cardiac magnetic resonance.
RESULTS The mean change in LVEF between baseline and follow-up for all patients was 4 6% (p¼ 0.006). Change in
LVEF and LVESV over time did not differ signiﬁcantly among the 4 groups. Patients actively treated with any stem cell
approach showed similar changes in LVEF and LVESV versus control subjects, with a small but signiﬁcant reduction in
infarct area (p ¼ 0.038).
CONCLUSIONS In our study, 3 different bone marrow–derived stem cell approaches in AMI did not result in
improvement of LVEF or volumes compared with standard AMI care (Trial of Hematopoietic Stem Cells in Acute
Myocardial Infarction [TECAM]; NCT00984178) (J Am Coll Cardiol 2015;65:2372–82) © 2015 by the American College of
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2373AB BR E V I A T I O N S
AND ACRONYM S
AMI = acute myocardial
infarction
BMMC = bone marrow
mononuclear cell(s)
CD = cluster of differentiation
CI = conﬁdence interval
CMR = cardiac magneticI n the last decade, stem cell–based therapy hasbeen evaluated as a potential therapeutic optionfor patients with acute myocardial infarction
(AMI). Different routes of cell delivery have been
evaluated, but intracoronary injection of autologous
bone marrow mononuclear cells (BMMC) and mobili-
zation of endogenous stem cells by granulocyte
colony-stimulating factor (G-CSF) have attracted the
most attention.SEE PAGE 2383 resonance imaging
DES = drug-eluting stent(s)
G-CSF = granulocyte colony-
stimulating factor
HF = heart failure
LVEDV = left ventricular
end-diastolic volume
LVEF = left ventricular
ejection fraction
LVESV = left ventricular
end-systolic volume
PCI = percutaneous coronary
intervention
RCT = randomized clinical trial
STEMI = ST-segment elevation
myocardial infarction
TECAM = Terapia Celular
Aplicada al Miocardio
WMSI = wall motion score
indexRandomized clinical trials (RCTs) of these ap-
proaches have showed variable outcomes in terms of
improved cardiac contractile function and suppressed
left ventricular (LV) negative remodeling (1). How-
ever, the efﬁcacy of these two speciﬁc approaches has
never been compared nor has their combination been
tested. The aim of this clinical trial was to compare
the efﬁcacy of intracoronary injection of BMMC,
mobilization alone by G-CSF, or a combination of both
therapies (intracoronary injection of BMMC plus
G-CSF mobilization) with conventional treatment in
the acute phase of AMI.
METHODS
The TECAM (Trial of Hematopoietic Stem Cells in
Acute Myocardial Infarction) study was a randomized
(1:1:1:1), multicenter, open-label, single-blind, con-
trolled trial in patients with ST-segment elevation
AMI (STEMI) who were successfully reperfused to
compare the efﬁcacy of 3 different approaches to cell
therapy for preventing adverse ventricular remodel-
ing compared with conventional therapy.
This study is an academic clinical trial. The study
sponsors had no role in the study design, data
collection, data analysis, data interpretation, or
writing of this report. The corresponding authors had
full access to all study data and were responsible for
the decision to submit for publication.
PATIENT POPULATION. From November 2005 to
January 2010, patients were enrolled from 8 Spanish
hospitals. The patients were enrolled from the
following institutions: Instituto de Ciencias del
Corazón (n ¼ 81), Hospital General Universitario
Gregorio Marañón (n ¼ 21), Hospital Universitario
de Salamanca (n ¼ 5), Hospital Río Hortega (n ¼ 4),
Complejo Hospitalario de León (n ¼ 4), Hospital
Río Carrión de Palencia (n ¼ 3), Hospital de
Segovia (n ¼ 1), and Hospital General Yague de Burgos
(n = 1). Inclusion criteria were as follows: age $18
years, AMI diagnosis with cardiac enzyme release
and total summed ST-segment elevation $6 mm,
akinesis or hypokinesis in the infarct-related arteryarea, successful reperfusion either with pri-
mary percutaneous coronary intervention
(PCI) or post-ﬁbrinolysis PCI with a ﬁnal
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grade ﬂow, rapamycin drug-eluting stent
(DES) implantation in the infract-related ar-
tery, and adequate revascularization of the
remaining coronary arteries before stem cell
therapy. Exclusion criteria were as follows:
cardiogenic shock; suspicion or evidence of
infarct mechanical complication; history of
sustained ventricular tachycardia or atrial
ﬁbrillation; patient with cardiac deﬁbrillator
or candidate for its potential implantation;
investigational drug treatment in the previous
4 weeks; actual or potential use of antineo-
plastic drugs; oncology antecedents in the
last 5 years; previous treatment with trans-
myocardial laser revascularization; women
of childbearing potential; severe concomitant
disease-modifying patient’s survival during
the study; active bleeding or major surgery
within 2 weeks forbidding the use of heparin,
abciximab, or antiplatelet therapy; previous
malignant hematology disease or hypercoag-
ulability disorders; previous known renal
failure (creatinine >2.5 mg/dl); any kind of
stroke in the previous year or any episode ever
of hemorrhagic stroke; major surgery pending
in the next year; previously known vascular disease
that prevents catheterization; evidence of hyper-
sensitivity to G-CSF treatment (ﬁlgrastim); or inability
to give written informed consent.
Approval was obtained from national and institu-
tional ethics committees and informed written con-
sent was obtained from each patient. All patients
were then randomized using a central telephone
system. Blocking was used to generate the random
allocation sequence. The block lengths were 4-, 8-,
and successive 4-size blocks.
STUDY PROTOCOL AND STEM CELL APPROACHES.
The day of infarct-related artery revascularization
was deﬁned as Day 0. All patients were reperfused
with a rapamycin DES per protocol. On Day 1, patients
were randomly assigned to either: 1) intracoronary
injection of BMMC; 2) mobilization with G-CSF;
3) both therapies; or 4) conventional treatment of AMI
(control group).
G-CSF injection started immediately after
randomization, with a dose of 10 mg/kg/day subcuta-
neously and maintained for 5 days, both in the
mobilization-alone and combined groups. Treatment
with BMMC was performed on Days 3 to 5, again in
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total of 50 ml of bone marrow was aspirated under
local anesthesia from the iliac crest. The aspirate was
ﬁltered and centrifuged and isolated by Ficoll density
separation. The interface was collected and washed
twice with heparinized phosphate-buffered saline
and resuspended at approximately 5 x 106 cells/ml
in heparinized saline. Just before intracoronary in-
jection, a small BMMC sample was collected for
cytometry studies (FACScalibur, BD Biosciences, San
Jose, California) for cluster of differentiation (CD)
34þ, CD117þ, CD133þ, and cell viability analyzed
using trypan blue reagent. An over-the-wire balloon
catheter positioned at the site of stent implantation
was inﬂated at 2 to 4 atm until complete block of
blood ﬂow. Then, the guidewire was retired and
the BMMC suspension was infused with a pump at 1
to 2 ml/min during 3-minute periods of inﬂation
and cell infusion alternating with 1 minute of dein-
ﬂation and reperfusion until the total BMMC dose
was given.
FOLLOW-UP. Follow-up included clinical evaluation
at baseline, 30 days, and every 3 months up to
12 months; determination of creatine kinase, creatine
kinase MB, and cardiac troponin T before and 24 h
after transplantation; continuous electrocardiog-
raphy monitoring from randomization to hospital
discharge; echocardiography and cardiac magnetic
resonance imaging (CMR) at baseline and 12 months;
and cardiac catheterization at baseline (after ran-
domization) and 12 months, including LV angiog-
raphy and coronary angiography. Any of the
following were regarded as major cardiac events:
death of any origin, reinfarction, heart failure (HF),
rehospitalization, target-vessel revascularization,
and ventricular arrhythmias or syncope.
LV FUNCTION ASSESSMENTS. CMR was performed
by means of scanners operating at 1.5-T. Image
acquisition was done as previously described (2). In
brief, global and regional LV function was assessed
with breath-hold cineCMR in the cardiac short axis,
vertical axis, and horizontal long axis. A 16-segment
model was used, and each ventricular segment was
given a score according to its motion: 1 ¼ normal,
2 ¼ hypokinetic, 3 ¼ akinetic, and 4 ¼ dyskinetic. Wall
motion score index (WMSI) was calculated from
the sum of the segmental scores divided by the
segments visualized. A late gadolinium enhance-
ment study was performed 15 min after intrave-
nous administration of 0.2 mmol/kg body weight
gadolinium-diethylene-triaminepentaacetate. Micro-
vascular obstruction was deﬁned as late hypo-
enhancement within a hyperenhanced region on lategadolinium enhancement images. Infarct size was
identiﬁed as the zone of bright signal on late-
enhanced images and was related to LV myocardial
mass to calculate infarct area. LV volumes and ejec-
tion fraction were calculated with the use of Mass
CMS software (Advion, Inc., Ithaca, New York).
LV angiograms were obtained in identical standard
projections at baseline and at 12 months. LV ejection
fraction (LVEF), LV end-systolic volume (LVESV), and
LV end-diastolic volume (LVEDV) were calculated by
the area-length method with the use of CMS software
version 6.0 (Medism, Leiden, the Netherlands).
All CMR, coronary angiograms, and LV angiogra-
phies were analyzed at an independent central
imaging core laboratory (ICICORELAB, Valladolid,
Spain) blinded to patient treatment assignment.
STUDY ENDPOINTS. The primary endpoint was ab-
solute change in global LVEF and in LVESV from
baseline to 12 months, as measured by CMR. Sec-
ondary endpoints included changes in LVEDV, infarct
size, infarct area, WMSI, and clinical events. Speciﬁed
subgroup analyses were conducted to determine
whether there was an interaction of the primary
endpoint with baseline LVEF, time to PCI, infarct
location, age, and microvascular obstruction. Based
on our previous published data (2), we calculated that
we would need a total of 88 patients (22 in each
group) to detect a difference in global LVEF change of
5%, as measured by CMR, with an 80% power and a
2-sided alpha level of 0.05. We estimated follow-up
loss and adjusted the sample size to 30 patients in
each group.
DATA COLLECTION AND STATISTICAL ANALYSIS. Data
were entered using a double-entry system and the
accuracy of collected data was validated against
medical records by an independent clinical research
organization (Chiltern International Spain SA,
Madrid, Spain). Data were then submitted to the data-
coordinating center (Hospital Gregorio Marañón).
Clinical outcome was adjudicated by an independent
clinical events committee, blinded to study group
assignment. A separate data and safety monitoring
board, not afﬁliated with the study investigators,
reviewed data periodically throughout the trial to
identify potential safety issues and monitor study
conduct.
Mean  standard deviation, median, maximal,
minimal, and number of observations were used to
describe continuous variables, and frequencies were
calculated for categorical variables. Differences be-
tween groups were assessed using 1-way breakdown
analysis of variance for continuous variables or
nonparametric tests when necessary. Categorical
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the Fisher exact tests when necessary. Conﬁdence
intervals (CIs) were calculated to estimate the differ-
ence between 2 means when necessary. A p value
<0.05 was considered to indicate statistical signiﬁ-
cance. All reported p values are 2-sided. Statistical
analyses were performed with PASW (SPSS) software
version 18 (IBM Corporation, Armonk, New York).
RESULTS
ENROLLMENT AND BASELINE CHARACTERISTICS.
Figure 1 shows the trial proﬁle. A total of 120 patients
with AMI successfully reperfused by means of rapa-
mycin DES implantation gave written informed
consent to participate in the trial. Thirty patientsFIGURE 1 Trial Proﬁle
30 Assigned to Cells
1 Claustrophobia
2 Defibrillator/pacemaker
1 Inadequate images
1 Claustrophobia
1 Withdrew
3 Refused
1 Inadequate images
2 Medical decision
1 Withdrew
3 Refused
1 MRI under repair
2 Defibrillator/pacema
2 Inadequate images
2 Inadequate images
4 Baseline and follow-up MRI not 
available
2 Baseline and follow-up LV
angiograms not available
28 Baseline and follow-up LV
angiograms available
23 Baseline  and follow-u
angiograms available
26 Baseline and follow-up MRI
available
20 Baseline and follow-u
available
7 Baseline and follow-up 
angiograms not available
30 Clinical follow-up available 30 Clinical follow-up ava
10 Baseline and follow-up
 not available
0 Intracoronary infusion not
performed
0 G-CSF not administered
30 Assigned to G-CSF
A total of 120 patients with reperfused acute myocardial infarction were
factor (G-CSF), both (G-CSF plus cells), or standard therapy (no aspirati
resonance imaging (MRI), left ventricular (LV) angiograms, and clinical fwere randomly assigned to receive BMMC, 30 to
G-CSF, 29 to BMMC plus G-CSF, and 31 to a control
group where no aspiration or sham infusion was
performed.
Baseline characteristics did not differ signiﬁcantly
among the 4 groups and revealed a typical distribu-
tion of risk factors and evidence-based medication
(Table 1). Thirty-one (26%) patients were reperfused
using primary PCI and 89 (74%) using post-
ﬁbrinolysis PCI; 37 patients underwent rescue PCI
and 52 patients delayed PCI. All 4 groups were well-
balanced in terms of reperfusion times, with a
median time from symptom onset to initial reperfu-
sion (primary PCI or ﬁbrinolysis) <5 h. Delays were
similar to those reported in our previous intervention
trials in patients with STEMI (3,4). After PCI, all1,150 Eligible patients
120 Randomized
1 Withdrew
2 Refused
2 Medical decision
1 MRI under repair
ker
2 Defibrillator/pacemaker
1 Inadequate images
p LV
p MRI
LV
1 Medical decision
1 Withdrew
2 withdrew
1 Died
1 Died
3 Inadequate images
3 Inadequate images
1 Refused
2 Refused
2 Withdrew
2 Refused
3 Baseline and follow-up LV
angiograms not available
10 Baseline and follow-up LV
angiograms not available
ilable
26 Baseline and follow-up LV
angiograms available
21 Baseline and follow-up LV
angiograms available
22 Baseline and follow-up MRI
available
24 Baseline and follow-up MRI
available
29 Clinical follow-up available 31 Clinical follow-up available
7 Baseline and follow-up MRI not 
available
7 Baseline and follow-up MRI not 
available
 MRI
0 G-CSF and/or intracoronary
infusion not performed
0 Standard therapy not performed
29 Assigned to G-CSF + Cells 31 Assigned to standard therapy
464 Never proposed to the patient
42 Did meet exclusion criteria
492 Included in other clinical trial
152 Refused to participate
randomized to receive cells (bone marrow mononuclear cells), granulocyte colony-stimulating
on or sham infusion performed). The chart includes baseline and follow-up cardiac magnetic
ollow-up available.
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With respect to cell transfer, median and range
time from bone marrow collection to cell delivery
was 21 h (16 to 24 h) with no signiﬁcant difference
among groups. Centrifugation and resuspension
reduced cell volume from bone marrow harvest to a
ﬁnal volume of 10 ml, which we injected into the
infarct-related coronary artery and which contained a
median quantity of BMMC almost 7 times higher in
patients previously treated with G-CSF versus those
who did not receive G-CSF (560 vs. 83 x 106 cells;
p < 0.001). The phenotypic characteristics of the
injected cells are shown in Table 1. Of note, variability
of bone marrow aspiration volume, number of injec-
ted cells, and percentage and absolute number of
progenitors was high between patients.
LV FUNCTION VARIABLES. Paired (baseline and
follow-up) LV assessments were available in 92 pa-
tients by CMR (n ¼ 26, BMMC group; n ¼ 20, G-CSF
group; n ¼ 22, combined group; and n ¼ 24, control
group) and in 98 patients undergoing LV angiography
(n ¼ 23, BMMC group; n ¼ 28, G-CSF group; n ¼ 26,
combined group; and n ¼ 21, control group). Reasons
why 28 paired magnetic resonance imaging and 22
paired LV angiographies were not available are
explained in Figure 1.
Table 2 shows baseline and follow-up CMR param-
eters. After 12 months, CMR showed no signiﬁcant
improvement in LVEF (baseline 48  9%, follow-up 52
 10%, overall 4  6%; 95% CI: 1.15 to 6.65; p ¼ 0.006).
The individual analysis for each group showed a sig-
niﬁcant increase of LVEF in comparison with baseline
values only for the BMMC group (95% CI: 0.70 to 10.58;
p ¼ 0.026), with similar trends for the G-CSF group
(95% CI: -3.99 to 8.49; p ¼ 0.470), the combined group
(95% CI: -1.61 to 9.15; p ¼ 0.164), and the control group
(95% CI: -1.43 to 9.09; p ¼ 0.150). Of note, comparison
of the absolute change in LVEF relative to baseline, 1
of our 2 speciﬁed primary endpoints, showed no sig-
niﬁcant difference among our 4 study groups.
LVESV and LVEDV remained almost unchanged
from baseline to 12-month assessment for all patients;
from 83  27 to 80  31 (p ¼ 0.592) for LVESV and from
157  31 to 166  39 (p ¼ 0.104) for LVEDV. Similarly,
changes in LVESV and LVEDV did not differ over time
for any individual randomized group. Neither the
absolute change in LVESV relative to baseline, our
second speciﬁed primary endpoint, nor the absolute
change in LVEDV showed signiﬁcant differences
among the 4 comparison groups.
With respect to other CMR-determined LV efﬁcacy
parameters, mean infarct size signiﬁcantly decreasedfrom 21  13 g at baseline to 14  9 g at 12 months
(4  6% for all patients; 95% CI: -3.78 to -10.22; p <
0.001). The individual analysis for each group showed
a signiﬁcant decrease in infarct size versus baseline
values for the BMMC group (95% CI: -0.40 to -12.62;
p ¼ 0.042), the G-CSF group (95% CI: -0.98 to -14.34;
p ¼ 0.026), and the combined group (95% CI: -3.79
to -15.25; p ¼ 0.002), with no signiﬁcant differences
among control subjects (95% CI: -11.22 to 2.50; p ¼
0.207). However, comparison of the absolute reduc-
tion in infarct size relative to baseline showed no
signiﬁcant difference among the study groups. Also,
all groups demonstrated similar overall infarct size.
Finally, regional contractility improved, as de-
monstrated by a signiﬁcantly better WMSI of the
infarcted wall, between baseline (1.56  0.25) and
follow-up (1.39  0.24); for all patients, -0.18  0.17
percentage points (95% CI: -0.11 to -0.25; p < 0.001).
The individual analysis for each randomized group
indicated a better WMSI of the infarcted wall over
baseline values for BMMC injection (95% CI: -0.05
to -0.30; p ¼ 0.007), G-CSF administration (95% CI:
0.01 to -0.35; p ¼ 0.062), BMMC injection and G-CSF
administration (95% CI: -0.08 to -0.35; p ¼ 0.002),
and standard of care (95% CI: -0.04 to -0.32; p ¼
0.021); but again, there was no signiﬁcant difference
based on absolute change in WMSI of the infarcted
wall relative to baseline for any of the groups studied.
LV angiography reproduced exactly the ﬁndings
observed by CMR for LVEF, LVESV, and LVEDV
(Table 2).
PROCEDURAL SAFETY AND CLINICAL OUTCOMES. Two
patients receiving intracoronary injection of BMMC
(1 each in the BMMC and combined groups) presented
periprocedural MI, deﬁned as troponin elevation of
at least 50% with respect to the troponin level before
BMMC injection, with excellent clinical resolution. In
patients treated with G-CSF, white blood cell count
increased markedly during G-CSF administration,
with no alteration in other rheology parameters, such
as serum ﬁbrinogen and blood viscosity. There was no
evidence of transiently elevated body temperature or
relevant bone pain, or any adverse events related to
G-CSF administration.
Occurrence of major adverse cardiac events did not
signiﬁcantly differ among groups (Table 3). We noted
no differences in treatment-related tachyarrhythmia
on electrocardiography monitoring. Triplets (3 suc-
cessive premature ventricular complexes and non-
sustained ventricular tachycardias) were observed
during hospitalization: 5 patients with BMMC injec-
tion, 5 patients with G-CSF, 3 patients from the
combined group, and 6 control subjects. One BMMC
TABLE 1 Baseline Characteristics
BMMC
(n ¼ 30)
G-CSF
(n ¼ 30)
BMMC þ G-CSF
(n ¼ 29)
Control Subjects
(n ¼ 31) p Value
Age, yrs 54  11 57  9 56  8 57  11 0.591
Male 29 (97) 25 (83) 25 (86) 28 (90) 0.375
Hypertension 8 (27) 12 (40) 9 (31) 14 (45) 0.426
Diabetes mellitus 5 (17) 3 (10) 7 (24) 3 (10) 0.356
Hyperlipidemia 17 (57) 15 (50) 11 (38) 11 (35) 0.299
Smoking history 25 (83) 26 (87) 21 (72) 24 (77) 0.529
Family history of coronary disease 5 (17) 6 (20) 7 (24) 10 (32) 0.508
Previous history of coronary disease 2 (7) 3 (10) 1 (3) 1 (3) 0.644
Coronary artery disease 0.693
1-vessel disease 23 (77) 22 (73) 22 (76) 22 (71)
2-vessel disease 6 (20) 8 (27) 7 (24) 7 (23)
3-vessel disease 1 (3) 0 (0) 0 (0) 2 (6)
Infarct-related artery 0.077
Left anterior descending coronary artery 20 (67) 20 (67) 24 (83) 21 (68)
Left circumﬂex artery 0 (0) 4 (13) 0 (0) 1 (3)
Right coronary artery 10 (33) 6 (20) 5 (17) 9 (29)
PCI in noninfarct-related arteries 18 (60) 14 (47) 15 (52) 20 (65) 0.497
Time from symptom onset to primary PCI, h 4 (3–6) 3 (2–5) 4 (1–6) 3 (3–7) 0.818
Time from symptom onset to post-ﬁbrinolysis PCI, h 14 (8–23) 18 (8–30) 16 (7–23) 17 (9–23) 0.779
Maximal creatine kinase, x ULN 3,641  3,075 2,880  1,494 3,838  1,930 2,980  2,179 0.247
Maximal creatine kinase MB, x ULN 337  262 321  198 350  223 328  209 0.972
Maximal troponin T, x ULN 11  8 13  30 22  45 19  37 0.514
NT-proBNP at randomization, x ULN 1,213  1,444 1,178  1,165 1,400  698 1,836  1,657 0.361
Time from reperfusion to G-CSF administration, h 39 (27–44) 44 (30–48) 0.251
Time from reperfusion to intracoronary
infusion of cells, h
190 (164–216) 190 (178–212) 0.358
Bone marrow aspiration volume, ml 60 (31–65) 55 (20–70) 0.319
Number of injected cells, x 106 83 (60–117) 560 (351–915) <0.001
Viability, % 89  9 91  6 0.321
CD34þ, % 1.03 (0.41–1.08) 0.31 (0.19–1.14) <0.001
CD34þ, absolute number x 106 0.83 (0.33–2.07) 2.93 (0.69–22.6) <0.001
CD133þ, % 0.55 (0.24–0.85) 0.23 (0.08–0.41) <0.001
CD133þ, absolute number x 106 0.38 (0.15–1.1) 2.4 (0.4–14.3) <0.001
CD117þ, % 1.27 (0.67–2.04) 0.4 (0.19–1.6) <0.001
CD117þ, absolute number x 106 1.14 (0.37–2.78) 3.23 (0.81–32.7) <0.001
Medication at discharge
Aspirin 27 (90) 29 (100) 25 (93) 30 (97) 0.314
Clopidogrel 30 (100) 29 (100) 27 (100) 30 (97) 0.424
Beta-blocker 28 (93) 24 (83) 24 (89) 29 (94) 0.481
ACE inhibitor or AT II blocker 26 (87) 24 (83) 23 (85) 23 (74) 0.588
Diuretics 2 (7) 3 (11) 4 (15) 2 (7) 0.670
Statins 28 (93) 28 (97) 27 (100) 30 (97) 0.590
Medication at 12 months follow-up
Aspirin 27 (90) 27 (93) 26 (96) 26 (87) 0.603
Clopidogrel 29 (97) 28 (97) 27 (100) 30 (100) 0.579
Beta-blocker 26 (87) 26 (89) 25 (93) 27 (90) 0.909
ACE inhibitor or AT II blocker 29 (97) 26 (90) 27 (100) 29 (97) 0.271
Diuretics 0 (0) 4 (14) 8 (30) 6 (20) 0.017
Statins 30 (100) 29 (100) 26 (96) 29 (97) 0.548
Values are mean  SD, n (%), or median (range with the minimal and maximal observations).
ACE ¼ angiotensin-converting enzyme; AT ¼ angiotensin; BMMC ¼ bone marrow mononuclear cell(s); CD ¼ cluster of differentiation; G-CSF ¼ granulocyte colony-stimulating factor;
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; PCI ¼ percutaneous coronary intervention; ULN ¼ upper limit of normal.
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TABLE 2 Quantitative Measures of LV Function
BMMC G-CSF BMMC þ G-CSF Control Subjects p Value
CMR 26 20 22 24
Global LV ejection fraction, %
Baseline 49  8 54  9 45  9 47  8 0.008
Follow-up 55  10 56  10 48  8 51  10 0.050
Absolute difference 6  6 2  5 4  7 4  7 0.365
End-diastolic volume, ml
Baseline 148  26 159  31 163  32 161  34 0.308
Follow-up 160  46 159  31 171  39 174  37 0.436
Absolute difference 12  51 -0.1  30 8  25 12  32 0.524
End-systolic volume, ml
Baseline 77  23 77  25 91  29 86  29 0.230
Follow-up 74  36 70  24 89  28 88  32 0.103
Absolute difference -3  26 -7  15 -2  19 2  24 0.362
Infarct size, g
Baseline 20  13 19  12 28  11 18  14 0.068
Follow-up 13  10 12  9 18  8 12  9 0.110
Absolute difference -6  12 -9  8 -10  9 -4  10 0.113
LV muscle mass, g
Baseline 126  22 127  24 129  20 136  18 0.363
Follow-up 114  20 105  23 116  22 120  22 0.157
Absolute difference -12  15 -21  11 -13  16 -16  17 0.216
Infarct size in relation to LV muscle mass, %
Baseline 16  11 16  10 22  7 14  10 0.111
Follow-up 12  9 11  9 16  7 12  8 0.112
Absolute difference -4  10 -6  5 -5  7 -1  7 0.062
Wall motion score index
Baseline 1.51  0.23 1.50  0.26 1.71  0.25 1.54  0.21 0.012
Follow-up 1.34  0.22 1.33  0.29 1.50  0.19 1.38  0.24 0.065
Absolute difference -0.17  0.18 -0.17  0.16 -0.21  0.18 -0.16  0.17 0.773
LV angiogram 28 23 26 21
Global LV ejection fraction, %
Baseline 50  12 54  14 47  13 49  12 0.268
Follow-up 58  14 58  14 50  12 52  12 0.051
Absolute difference 8  12 5  13 3  12 3  13 0.413
End-diastolic volume, ml
Baseline 140  34 132  30 133  30 127  37 0.559
Follow-up 148  32 141  37 146  37 137  35 0.707
Absolute difference 8  44 9  37 13  34 10  45 0.963
End-systolic volume, ml
Baseline 69  19 62  26 70  21 67  33 0.667
Follow-up 61  26 60  27 74  29 66  28 0.244
Absolute difference -8  24 -2  21 3  26 -1  32 0.467
Values are n or mean  SD.
CMR ¼ cardiac magnetic resonance imaging; LV ¼ left ventricular; other abbreviations as in Table 1.
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electrical storm and monomorphic sustained ven-
tricular tachycardia 3 days after cell transplantation,
even though there was no periprocedural complica-
tion. This patient received an implantable
cardioverter-deﬁbrillator after ruling out coronary
reocclusion. During follow-up, 1 G-CSF patient pre-
sented with episodes of nonsustained ventricular
tachycardias 3 months post-AMI. He received an
implantable cardioverter-deﬁbrillator after showingsyncopal sustained ventricular tachycardias through
programmed electrophysiological study. Three addi-
tional deﬁbrillators were implanted during follow-up
for primary prevention (1 BMMC patient, 2 combined
group patients). One G-CSF patient required pace-
maker implantation for complete auriculoventricular
block development. In addition to the 2 previously
described periprocedural myocardial infarctions, 1
BMMC patient presented with an acute in-stent
thrombosis that was successfully treated with 2
TABLE 3 Clinical Events
BMMC
(n ¼ 30)
G-CSF
(n ¼ 30)
BMMC þ G-CSF
(n ¼ 29)
Control Subjects
(n ¼ 31) p Value
Death 0 (0) 0 (0) 0 (0) 1 (3.2) 0.408
Recurrence of
myocardial infarction
2 (6.7) 0 (0) 1 (3.4) 0 (0) 0.283
Heart failure 1 (3.3) 2 (6.7) 2 (6.9) 5 (16.1) 0.304
Rehospitalization 3 (10) 3 (10) 1 (3.4) 3 (9.7) 0.754
Ventricular arrhythmia
or syncope
6 (20.0) 6 (20.0) 3 (10.3) 6 (19.4) 0.714
Any event 8 (26.7) 10 (33.3) 5 (17.2) 9 (29) 0.554
Values are n (%).
Abbreviations as in Table 1.
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congestive HF requiring therapy were observed dur-
ing follow-up in 10 patients: 1 with BMMC injection,
2 with G-CSF, 2 with BMMC plus G-CSF, and 5 control
subjects. One control patient who developed HF died
during follow-up.
Because patient number was limited and may have
had an impact on LV outcome parameters, we
analyzed the impact of any active cell therapy
compared with the control group. At 12 months, there
were no differences between active treatment and
control subjects based on absolute changes in LVEF,
LVEDV, LVESV, and WMSI. Although infarct size
decreased over time in control subjects and in pa-
tients with active therapy, the absolute change in
myocardial infarct area was signiﬁcantly greater after
active therapy, decreasing from 19  10% at baseline
to 13  8% at 12-month follow-up, with an absolute
change of -5  7 percentage points (95% CI: -0.21
to -7.20; p ¼ 0.038) (Central Illustration).
The lack of any additional active treatment effect
on LVEF and remodelling was consistent across clin-
ically relevant subgroups (baseline LVEF, time from
bone marrow collection to cell delivery, time to PCI,
infarct location, age, and microvascular obstruction).
DISCUSSION
The randomized TECAM study shows a lack of rele-
vant clinical beneﬁt in global LV functional recovery
after 12 months for patients with STEMI treated by 1
of 3 different approaches: intracoronary injection of
BMMC, mobilization with G-CSF, or combined BMMC
and G-CSF versus standard AMI care. Although a
modest 4% improvement in LVEF was found overall,
comparable with contemporary randomized reperfu-
sion trials in patients with similar characteristics
(3,4), none of the intervention groups showed greatly
increased LVEF compared with control subjects.
Furthermore, LV volumes did not differ among the
treated groups at baseline or at 12-month follow-up,
refuting our primary hypothesis that in timely
reperfused AMI, any of the aforementioned cell
therapies would signiﬁcantly augment LV functional
recovery, increasing LVEF or decreasing LVESV over
time. Results were consistent for both imaging
methods used: CMR and LV angiography.
Because patient number was limited and may have
impacted LV outcome parameters, we grouped all
patients receiving active treatment and compared
them with the standard care group. Although the
absolute change in LVEF and volumes over time
showed no signiﬁcant differences, reduction of the
infarct area over 12 months, as measured by serialcontrast-enhanced CMR, was signiﬁcantly greater
with active treatment compared with control sub-
jects. This additional reduction in myocardial infarct
area suggests a potentially interesting biological
effect of cell-based therapy on infarct remodeling and
is consistent with previous RCTs of BMMC intra-
coronary injection (5) or G-CSF mobilization (6).
However, without enhanced recovery of regional
function in infarcted segments, we should be
cautious not to overestimate this ﬁnding, which must
be conﬁrmed in future RCTs.
The TECAM trial is unique for several reasons. First
of all, in patients with AMI, BMMC injection has been
compared in 23 RCTs (5,7-28) and mobilization by G-
CSF alone in 9 RCTs (6-14), but ours is the ﬁrst RCT to
explore combining the 2 in patients with AMI. A
similar approach with G-CSF therapy and subsequent
intracoronary infusion of collected peripheral blood
stem cells improved LVEF and cardiac remodeling in
patients with AMI (15,16). In our experience, the
combined strategy did not improve global or regional
function at 12 months compared with control sub-
jects. Moreover, our use of CMR, currently considered
the gold standard for primary endpoint measures of
efﬁcacy, has to be underlined. To date, 9 (39%) BMMC
injection RCTs (5,9,14,20,22,24,25,27,28), and 3 (33%)
G-CSF mobilization RCTs (6,10,11), used CMR.
Because patient number may have limited our study
and inﬂuenced LV outcome parameters, it is impor-
tant to put into perspective the number of paired
CMR studies performed in our actively treated pa-
tients (n ¼ 68), which surpasses all but 3 previous
studies of intracoronary BMMC injection, which
analyzed 139 (17), 107 (28), and 75 (18) CMR studies.
We also had more paired CMR studies than any of the
previous G-CSF RCTs (10,11,6). Thus, our trial reaches
one of the highest rates of paired CMR studies to date.
The TECAM trial conﬁrms the lack of effect of
intracoronary BMMC infusion on LV cardiac func-
tion seen in a meta-analysis of RCTs that used
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In comparing absolute differences in indices of left ventricular (LV) cardiac remodeling in patients with reperfused ST-segment elevation
myocardial infarction, a bone marrow–derived stem cell approach only signiﬁcantly improved infarct area (%) over control subjects;
no differences were seen in ejection fraction (LVEF, %), end-diastolic volume (LVEDV, ml), end-systolic volume (LVESV, ml), infarct size (g),
or wall motion score index (WMSI). Values are means (bars) and standard deviations (lines).
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results for G-CSF therapy are consistent with previous
RCTs using CMR (6,10,11), and a general meta-analysis
(25). In contrast to previous studies (26,27), and
in agreement with previous RCTs, there was no
improvement in the recovery of LV function among
patients with more depressed LVEF at baseline.
A positive correlation has been suggested between
the BMMC dose infused and the LVEF effect
measured by CMR. However, this observation was
raised by a recent meta-analysis and by a post-hoc
analysis (1,28), with the only RCT study to date
designed to test that hypothesis (29), randomizing
patients to either higher (108) or lower (107) BMMC
injection, also failing to show any difference in LVEF
or improvement in volumes. The TECAM trial repre-
sents an excellent opportunity to analyze whether the
number of transplanted cells could be associated with
an improvement in LV function. When comparing
patients randomized to injection of BMMC alone
(83  106 cells) with patients receiving injection
of BMMC after G-CSF mobilization (560 x 106 cells;p < 0.001), no difference was seen in the absolute
change in LVEF (5.6  6.1 vs. 3.8  7.2, respectively;
p ¼ 0.347) or LVESV (-3.0  26 vs. -1.8  19, respec-
tively; p ¼ 0.856) despite the fact the absolute
numbers of CD34þ, CD133þ, and CD117þ progenitor
cells injected were higher in the combined group.
One of the most controversial considerations with
bone marrow–derived stem cell therapy is whether it
affects clinical outcome in patients with AMI. The
meta-analysis by Jeevanantham et al. (30) showed a
reduction in all-cause mortality, cardiac mortality,
recurrent AMI, hospitalization for HF, and in-stent
thrombosis after BMMC transplantation. In contrast,
the meta-analysis by de Jong et al. (24) described no
beneﬁcial effect on major adverse cardiac and cere-
brovascular events. Active bone marrow–derived
therapy in our RCT did not lead to a reduction in
clinical outcomes at 12 months.
STUDY LIMITATIONS. There are several limitations
and potential explanations why this study was
neutral. First, the randomized TECAM trial had
an open-label design. Also, patient numbers were
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Intracoronary
injection of bone marrow–derived autologous mononuclear cells
alone or in combination with granulocyte colony-stimulating
factor mobilization does not improve left ventricular function
12 months after primary percutaneous revascularization in
patients with ST-segment elevation myocardial infarction.
TRANSLATIONAL OUTLOOK: Further studies involving
different cells and delivery methods and longer-term clinical
endpoints are needed to effectively modify adverse ventricular
remodeling and improve survival and quality of life for victims of
acute myocardial infarction.
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parameters. No adverse remodeling was observed in
the control group, probably explained by well-
established regional systems of STEMI care and goals
for reperfusion therapy in our country (3,4). Also,
because of our regional reperfusion systems, patients
treated with cells presented no large necrosis with a
baseline LVEF of 48  9% where signiﬁcant improve-
ment is more difﬁcult to evidence. Variability of
innate donor BMMC diversity and bone marrow health
also is high in BMMC RCTs, as it was in the TECAM
trial. Finally, it has been suggested that the use of
heparin in BMMC suspension might decrease cell
homing (31). We used heparin for BMMC cell prepa-
ration and during intracoronary infusion in all cases.
CONCLUSIONS
We evaluated 3 different bone marrow–derived stem
cell approaches (intracoronary injection of BMMC,
mobilization with G-CSF, or both) in patients with
AMI, but none resulted in improvement of LVEF or
LV volumes versus standard AMI care, whether
measured by CMR or angiography.
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